Forest deal settling US government probe on kickbacks covers civil claims only
This article was originally published in Scrip
Recent court documents show that Forest Laboratories and the US Department of Justice agreed to settle civil claims arising from a government probe into the marketing of the SSRI antidepressants Celexa (citalopram) and Lexapro (escitalopram) for unapproved paediatric use and the paying of kickbacks to physicians. Now, in a regulatory filing, Forest has disclosed that the pact does not cover an ongoing probe into possible criminal violations related to those products and the hypothyroidism treatment Levothroid.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.